| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood NCT03589729 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Posit NCT03147612 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700 | Stanford University | Phase 1 |
| Completed | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in NCT01858740 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Re NCT01428635 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Active Not Recruiting | Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia NCT01424982 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive NCT00390793 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor He NCT00068718 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |